Should Competitors of Negotiated Drugs Review Their Market Strategies?
Manufacturers of therapeutic alternatives to negotiation-eligible drugs should re-examine their commercialization strategies in response to market dynamics.
We partner closely with clients to ensure their IRA strategy is tailored to their industry position, needs, and goals, helping clients make informed decisions and achieve long-term success.
The Inflation Reduction Act brings some of the biggest changes affecting the pharmaceutical industry in the last decade. Megan West discusses how these shifts will impact pharmaceutical organizations and how Avalere can help develop strategies to mitigate risk and identify opportunities throughout the product lifecycle.
Manufacturers of therapeutic alternatives to negotiation-eligible drugs should re-examine their commercialization strategies in response to market dynamics.
Manufacturers of therapeutic alternatives to negotiation-eligible drugs should examine their value and evidence strategy in response to new dynamics.
IRA negotiation eligibility criteria may impact orphan drug investment, affecting long-term innovation and patient access.
Avalere’s expert presentations at the AXS23 Summit described IRA drug-pricing policies and the law’s impact on patient access and affordability.
Manufacturers may find significant gaps between their existing evidence and the negotiation data elements that CMS will evaluate during the negotiation process.
Stakeholders in the drug supply chain should consider operational complexities that will result from variable arrangements for accessing the MFP.
Avalere experts will explore the potential implications of the Inflation Reduction Act (IRA)’s Medicare drug price negotiation program guidance and discuss implementation strategies for the near- and long-term.
Ahead of the Asembia and ISPOR 2023 conferences, Avalere experts discuss the increasing importance of value and evidence strategies as part of Inflation Reduction Act (IRA) implementation planning.
A new Avalere analysis identified variability in Medicaid physician office, pharmacy, and Federally Qualified Health Centers vaccine reimbursement policies.
IRA inflation rebates and drug price negotiation will impact drug launch prices in Medicare, with spillover effects in the Medicaid and commercial markets.